9,984 Shares in Becton, Dickinson and Company (NYSE:BDX) Purchased by Continental Investors Services Inc.

Posted by Defense World Staff on Mar 18th, 2023

Continental Investors Services Inc. purchased a new position in Becton, Dickinson and Company (NYSE:BDX – Get Rating) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 9,984 shares of the medical instruments supplier’s stock, valued at approximately $2,485,000.

A number of other large investors also recently bought and sold shares of BDX. Tranquilli Financial Advisor LLC lifted its position in shares of Becton, Dickinson and by 4.8% in the 2nd quarter. Tranquilli Financial Advisor LLC now owns 912 shares of the medical instruments supplier’s stock valued at $225,000 after acquiring an additional 42 shares in the last quarter. Physicians Financial Services Inc. lifted its position in shares of Becton, Dickinson and by 1.0% in the 3rd quarter. Physicians Financial Services Inc. now owns 4,517 shares of the medical instruments supplier’s stock valued at $1,007,000 after acquiring an additional 46 shares in the last quarter. Valmark Advisers Inc. lifted its position in shares of Becton, Dickinson and by 1.0% in the 3rd quarter. Valmark Advisers Inc. now owns 4,800 shares of the medical instruments supplier’s stock valued at $1,070,000 after acquiring an additional 46 shares in the last quarter. Guardian Wealth Advisors LLC lifted its position in shares of Becton, Dickinson and by 5.6% in the 3rd quarter. Guardian Wealth Advisors LLC now owns 893 shares of the medical instruments supplier’s stock valued at $199,000 after acquiring an additional 47 shares in the last quarter. Finally, Equitable Holdings Inc. lifted its position in shares of Becton, Dickinson and by 3.7% in the 3rd quarter. Equitable Holdings Inc. now owns 1,330 shares of the medical instruments supplier’s stock valued at $296,000 after acquiring an additional 48 shares in the last quarter. Institutional investors and hedge funds own 87.08% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the subject of several research analyst reports. Piper Sandler upped their price target on shares of Becton, Dickinson and from $245.00 to $260.00 and gave the company a “neutral” rating in a research report on Thursday, February 2nd. StockNews.com initiated coverage on shares of Becton, Dickinson and in a research note on Thursday. They issued a “buy” rating on the stock. Bank of America upgraded shares of Becton, Dickinson and from a “neutral” rating to a “buy” rating and upped their price objective for the company from $250.00 to $290.00 in a research note on Tuesday, January 3rd. The Goldman Sachs Group dropped their price objective on shares of Becton, Dickinson and from $319.00 to $272.00 and set a “buy” rating on the stock in a research note on Wednesday, November 23rd. Finally, Morgan Stanley upped their price objective on shares of Becton, Dickinson and from $290.00 to $295.00 and gave the company an “overweight” rating in a research note on Friday, February 3rd. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $271.89.

Insider Activity at Becton, Dickinson and

In other Becton, Dickinson and news, EVP Richard Byrd sold 1,421 shares of the stock in a transaction on Friday, February 3rd. The shares were sold at an average price of $248.60, for a total value of $353,260.60. Following the completion of the sale, the executive vice president now directly owns 4,119 shares of the company’s stock, valued at approximately $1,023,983.40. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.31% of the stock is currently owned by company insiders.

Becton, Dickinson and Stock Performance

Shares of BDX opened at $235.58 on Friday. The company’s fifty day moving average is $244.55 and its 200-day moving average is $241.73. Becton, Dickinson and Company has a 12 month low of $215.90 and a 12 month high of $277.29. The firm has a market cap of $66.88 billion, a price-to-earnings ratio of 44.45, a price-to-earnings-growth ratio of 2.46 and a beta of 0.53. The company has a quick ratio of 0.60, a current ratio of 1.07 and a debt-to-equity ratio of 0.56.

Becton, Dickinson and (NYSE:BDX – Get Rating) last posted its earnings results on Thursday, February 2nd. The medical instruments supplier reported $2.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.30. Becton, Dickinson and had a net margin of 8.47% and a return on equity of 13.52%. The business had revenue of $4.59 billion for the quarter, compared to analyst estimates of $4.59 billion. During the same period last year, the business posted $3.64 EPS. Becton, Dickinson and’s revenue was down 2.8% compared to the same quarter last year. Equities analysts expect that Becton, Dickinson and Company will post 12.19 EPS for the current fiscal year.

Becton, Dickinson and Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 31st. Investors of record on Friday, March 10th will be paid a $0.91 dividend. The ex-dividend date of this dividend is Thursday, March 9th. This represents a $3.64 dividend on an annualized basis and a yield of 1.55%. Becton, Dickinson and’s payout ratio is presently 68.68%.

Becton, Dickinson and Company Profile

(Get Rating)

Becton, Dickinson & Co engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery.